Dishman Carbogen Amics (NSE:DCAL) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:DCAL Dishman Carbogen Amics Ltd NSE:DCAL
71 GF Score
Price ₹170.02
GF Value ₹236.74
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Dishman Carbogen Amics Research & Development?

Dishman Carbogen Amics NSE:DCAL -2.41% 71 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:DCAL with a GF Score™ of 71/100 and a GF Value™ of ₹236.74 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Dishman Carbogen Amics's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Dishman Carbogen Amics  (NSE:DCAL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Dishman Carbogen Amics Research & Development Related Terms

Dishman Carbogen Amics Research & Development Historical Data

* Premium members only.

The historical data trend for Dishman Carbogen Amics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dishman Carbogen Amics Research & Development Chart

Dishman Carbogen Amics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Dishman Carbogen Amics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:DCAL
71GF Score
Dishman Carbogen Amics Ltd NSE:DCAL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dishman Carbogen Amics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Dishman Carbogen Amics (NSE:DCAL) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Dishman Carbogen Amics and its competitors.
Is Dishman Carbogen Amics' Research & Development too high?
Dishman Carbogen Amics' current Research & Development is ₹0 Mil. Overall, Dishman Carbogen Amics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dishman Carbogen Amics' Research & Development compare to VRTX and REGN?
Dishman Carbogen Amics' Research & Development of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Dishman Carbogen Amics and its competitors. Dishman Carbogen Amics's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dishman Carbogen Amics stock overvalued right now?
Based on GuruFocus' analysis, Dishman Carbogen Amics (NSE:DCAL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹236.74, compared to a current price of ₹170.02 — trading 28.2% below its estimated fair value. The current Research & Development is ₹0 Mil. Dishman Carbogen Amics' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Dishman Carbogen Amics (NSE:DCAL), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dishman Carbogen Amics (NSE:DCAL) Overvalued in 2026?

Based on GuruFocus' analysis, Dishman Carbogen Amics stock appears to be undervalued. The current stock price of ₹170.02 is trading 28.2% below its estimated GF Value™ of ₹236.74. GuruFocus considers Dishman Carbogen Amics to be Modestly Undervalued.

Key valuation signals for NSE:DCAL:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹236.74 vs. price of ₹170.02 (28.2% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the NSE:DCAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dishman Carbogen Amics Business Description

Other Exchanges 540701:India
Address Iscon-Bopal Road, Dishman Corporate House, Ambli, Ahmedabad, GJ, IND, 380 058
Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India.
71GF Score

Get the complete analysis for NSE:DCAL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹170.02
Price
₹236.74
GF Value